SYPC

International Biosynthetic Enterprise

Company Profile

Fully-automated pharmaceutical company

Total assets over 300 million USD

Full manufacturing chain from pharmaceutical intermediates, APIs to FPFs

Major produtcts FDA and EDQM approved

Products export to over 50 countries

Manufacturing Capacity

540000㎡ fully-automated workshops

1200+ professionals(14% R&D personnel)

Annual production capacity:

10000 tons of APIs & intermediates

5 billion of OSD

600 million of powder for injection

Products

R&D and Innovation

Market Coverage Range

The global sales network covers more than 50 countries.

Mainly distributed in Europe, the United States, the Middle East, Africa and Southeast Asia, etc.

Medicine Catalog »

Enterprise Chronicles

2004

Established company and specialist in local anesthetic and antitussive APIs
2013

Put bismuth into production
2014

Merged with Xinghuo Pharma, introducing pediatric, respiratory, and cardiovascular drugs
2015

Commercial production of bio-enzymes & DHPG series
2016

Introducing trimebutine maleate API & FDFs
2022

Established SYPG and restructured business
2023

Newly-built Shuangyan bio-pharmaceutical industrial park
2024

Production for clavulanate & amoxicillin series

Put INJP into production

Potassium clavulanate with MCC & SiO₂ registered in India
2025

CEP for amoxicillin trihydrate powder/compacted & potassium clavulanate with MCC/SiO₂